Cited 47 times in
Epidermolysis bullosa acquisita
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김수찬 | - |
dc.contributor.author | 김종훈 | - |
dc.date.accessioned | 2014-12-18T09:55:38Z | - |
dc.date.available | 2014-12-18T09:55:38Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0926-9959 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89090 | - |
dc.description.abstract | Epidermolysis bullosa acquisita (EBA) is a chronic autoimmune subepidermal bullous disease with clinical features similar to the genetic form of dystrophic epidermolysis bullosa. EBA is characterized by the presence of autoantibodies against type VII collagen which is a major component of the anchoring fibrils at the dermal-epidermal junction. EBA can be divided into two main clinical types; mechanobullous and inflammatory EBA. Mechanobullous EBA, referred to as classic EBA, presents with skin fragility, blisters and dystrophic changes on trauma-prone areas. Inflammatory EBA resembles other autoimmune subepidermal bullous diseases. Compelling evidence from mouse models supports a pathogenic role of autoantibodies against type VII collagen in EBA. Treatment of EBA is often unsatisfactory. The most widely used systemic treatment is corticosteroids. Colchicine and dapsone have been reported to be good treatment modalities when combined with corticosteroids. Some intractable cases of EBA have successfully been treated with intravenous immunoglobulin or rituximab. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adrenal Cortex Hormones/therapeutic use | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibodies, Monoclonal, Murine-Derived/therapeutic use | - |
dc.subject.MESH | Autoantibodies/metabolism | - |
dc.subject.MESH | Autoimmune Diseases/diagnosis* | - |
dc.subject.MESH | Autoimmune Diseases/drug therapy* | - |
dc.subject.MESH | Autoimmune Diseases/etiology | - |
dc.subject.MESH | Colchicine/therapeutic use | - |
dc.subject.MESH | Collagen Type VII/immunology | - |
dc.subject.MESH | Dapsone/therapeutic use | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Epidermolysis Bullosa Acquisita/diagnosis* | - |
dc.subject.MESH | Epidermolysis Bullosa Acquisita/drug therapy* | - |
dc.subject.MESH | Epidermolysis Bullosa Acquisita/etiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulins, Intravenous/therapeutic use | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Rituximab | - |
dc.title | Epidermolysis bullosa acquisita | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Dermatology (피부과학) | - |
dc.contributor.googleauthor | J.H. Kim | - |
dc.contributor.googleauthor | S.-C. Kim | - |
dc.identifier.doi | 10.1111/jdv.12096 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00637 | - |
dc.contributor.localId | A05233 | - |
dc.relation.journalcode | J01783 | - |
dc.identifier.eissn | 1468-3083 | - |
dc.identifier.pmid | 23368767 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/jdv.12096/abstract | - |
dc.subject.keyword | Adrenal Cortex Hormones/therapeutic use | - |
dc.subject.keyword | Animals | - |
dc.subject.keyword | Antibodies, Monoclonal, Murine-Derived/therapeutic use | - |
dc.subject.keyword | Autoantibodies/metabolism | - |
dc.subject.keyword | Autoimmune Diseases/diagnosis* | - |
dc.subject.keyword | Autoimmune Diseases/drug therapy* | - |
dc.subject.keyword | Autoimmune Diseases/etiology | - |
dc.subject.keyword | Colchicine/therapeutic use | - |
dc.subject.keyword | Collagen Type VII/immunology | - |
dc.subject.keyword | Dapsone/therapeutic use | - |
dc.subject.keyword | Disease Models, Animal | - |
dc.subject.keyword | Epidermolysis Bullosa Acquisita/diagnosis* | - |
dc.subject.keyword | Epidermolysis Bullosa Acquisita/drug therapy* | - |
dc.subject.keyword | Epidermolysis Bullosa Acquisita/etiology | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Immunoglobulins, Intravenous/therapeutic use | - |
dc.subject.keyword | Mice | - |
dc.subject.keyword | Rituximab | - |
dc.contributor.alternativeName | Kim, Soo Chan | - |
dc.contributor.affiliatedAuthor | Kim, Soo Chan | - |
dc.contributor.affiliatedAuthor | Kim, Jong Hoon | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 27 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1204 | - |
dc.citation.endPage | 1213 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, Vol.27(10) : 1204-1213, 2013 | - |
dc.identifier.rimsid | 33795 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.